Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.68 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.68 |
| ▸ | PDE4A | P27815 | 1/20 | 0.68 |
| ▸ | KDR | P35968 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | AGPAT2 | O15120 | 3/20 | 0.57 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.57 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 5/20 | 0.54 |
| ▸ | RAB9A | P51151 | 5/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10910614 | 0.89 | CA12 (0.68) | ADORA3SLC6A2PDE4AKDRKMT2A | |
| SCHEMBL10878944 | 0.87 | ADORA3 (0.63) | ADORA3SLC6A2PDE4AKDRKMT2A | |
| SCHEMBL14869753 | 0.87 | ADORA3 (0.58) | ADORA3SLC6A2PDE4AKDRKMT2A | |
| SCHEMBL12135831 | 0.84 | NPC1 (0.75) | ADORA3SLC6A2PDE4AKDRKMT2A | |
| SCHEMBL11630110 | 0.84 | KCNH3 (0.59) | ADORA3SLC6A2PDE4AKDRKMT2A | |
| SCHEMBL14869745 | 0.83 | LMNA (0.55) | ADORA3SLC6A2PDE4AKDRKMT2A | |
| SCHEMBL14869705 | 0.83 | KCNH3 (0.73) | ADORA3SLC6A2PDE4AKDRCA1 | |
| Chlorazanil SCHEMBL180422 | 0.81 | ADORA3 (1.00) | ADORA3SLC6A2PDE4AKDRKMT2A | |
| Chlorazanil SCHEMBL29652081 | 0.81 | ADORA3 (1.00) | ADORA3SLC6A2PDE4AKDRKMT2A | |
| SCHEMBL4366463 | 0.81 | AGPAT2 (0.70) | ADORA3SLC6A2PDE4AKDRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113260450-A | Microencapsulation of fragrances | 科莱恩国际有限公司 | 2021-08-13 | — | — | CN | claimed |
| US-20110237587-A1 | 1,3,5-Triazine-2,4,6-Triamine Compound or Pharmaceutical Acceptable Salt Thereof, and Pharmaceutical Composition Comprising the Same | HANALL PHARMACEUTICAL COMPANY, LTD (KR) | 2011-09-29 | — | — | US | claimed |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2022-05-19 | — | — | US | disclosed |
| CN-113260450-A | Microencapsulation of fragrances | 科莱恩国际有限公司 | 2021-08-13 | — | — | CN | disclosed |
| US-11065215-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMA (US) LLC (US) | 2021-07-20 | — | — | US | disclosed |
| US-10668031-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMA (US) LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200138751-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2020-05-07 | — | — | US | disclosed |
| US-20190076380-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2019-03-14 | — | — | US | disclosed |
| US-10028923-B2 | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20140341986-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2014-11-20 | — | — | US | disclosed |
| US-8796338-B2 | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796338-B2 | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC (US) | 2014-08-05 | — | — | US | disclosed |
| WO-2013103384-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ELCELYX THERAPEUTICS, INC. (US) | 2013-07-11 | — | — | WO | disclosed |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20110237587-A1 | 1,3,5-Triazine-2,4,6-Triamine Compound or Pharmaceutical Acceptable Salt Thereof, and Pharmaceutical Composition Comprising the Same | HANALL PHARMACEUTICAL COMPANY, LTD (KR) | 2011-09-29 | — | — | US | disclosed |
| EP-2197858-A2 | 1,3,5-TRIAZINE-2,4,6-TRIAMINE COMPOUND OR PHARMACEUTICAL ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Hanall Pharmaceutical Company LTD. (KR) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009028891-A2 | 1,3,5-TRIAZINE-2,4,6-TRIAMINE COMPOUND OR PHARMACEUTICAL ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HANALL PHARMACEUTICAL COMPANY. LTD (KR) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237587-A1 | 1,3,5-Triazine-2,4,6-Triamine Compound or Pharmaceutical Acceptable Salt Thereof, and Pharmaceutical Composition Comprising the Same | TP53, TP53BP1, SLC5A1 | ADORA3 1739/4885SLC6A2 737/4885PDE4A 2816/4885 |
| US-10668031-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | ADORA3 900/4885SLC6A2 1508/4885PDE4A 251/4885 |
| US-11065215-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | ADORA3 900/4885SLC6A2 1508/4885PDE4A 251/4885 |
| US-20130095140-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GPR119 | ADORA3 900/4885SLC6A2 1508/4885PDE4A 251/4885 |
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | ADORA3 900/4885SLC6A2 1508/4885PDE4A 251/4885 |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | SLC5A2, SLC5A1, GPR119 | ADORA3 900/4885SLC6A2 1508/4885PDE4A 251/4885 |
| US-20190076380-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GPR119 | ADORA3 900/4885SLC6A2 1508/4885PDE4A 251/4885 |
| US-10028923-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | ADORA3 900/4885SLC6A2 1508/4885PDE4A 251/4885 |
| US-20200138751-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GCG | ADORA3 937/4885SLC6A2 1641/4885PDE4A 244/4885 |
| US-20140341986-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GPR119 | ADORA3 900/4885SLC6A2 1508/4885PDE4A 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.